ShengJing Hospital of China Medical University (China Medical University No.2 Ho spital )
🇨🇳China
MRE for Assessment of Histopathological Growth Patterns in Colorectal Liver Metastases
Recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Diagnostic Test: Magnetic Resonance Elastography and routine MRI
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06208397
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension
Recruiting
- Conditions
- CirrhosisLiver Portal Hypertension
- Interventions
- Device: 2D-MREDevice: 3D-MREDevice: HVPG
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06205992
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Biological: CadonilimabDrug: Eribulin
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 128
- Registration Number
- NCT06202313
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
Multifrequency MRE in Evaluation of Chronic Kidney Diseases
Recruiting
- Conditions
- Chronic Kidney Disease (CKD)
- Interventions
- Diagnostic Test: Magnetic Resonance Imaging
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06202235
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC
Phase 2
Recruiting
- Conditions
- Stereotactic RadiotherapyImmunotherapyBreast Cancer
- Interventions
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 136
- Registration Number
- NCT06165900
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
Chiglitazar/Metformin in Non-obese Women With PCOS
Phase 2
Completed
- Conditions
- Polycystic Ovary SyndromeChiglitazarMetformin
- Interventions
- Drug: ChiglitazarDrug: Metformin
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT06125587
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
Magnetic Resonance Elastography in Glioma: Exploring Tumor Stiffness and Adhesion
Not Applicable
Recruiting
- Conditions
- Glioma
- Interventions
- Diagnostic Test: Magnetic Resonance ElastographyProcedure: Assessment and Recording
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05990244
- Locations
- 🇨🇳
Shengjing Hospital, Shenyang, Liaoning, China
VTE Risk Prevention System Based on Big Data Analysis and Multimodule System
Recruiting
- Conditions
- Recruiting
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 100000
- Registration Number
- NCT05969951
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
MRE Evaluation for Spinal Cord Tumor Surgery: Stiffness and Adhesion Assessment
Not Applicable
Recruiting
- Conditions
- Spinal Cord Tumors
- Interventions
- Diagnostic Test: Magnetic Resonance ElastographyProcedure: Assessment and Recording
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05957679
- Locations
- 🇨🇳
Shengjing Hospital, Shenyang, Liaoning, China
rhBNP in Type 3 Pulmonary Hypertension
Phase 4
- Conditions
- Group 3 Pulmonary Hypertension
- Interventions
- Drug: recombinant human brain natriuretic peptideDrug: Placebo
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT05716984
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China
© Copyright 2025. All Rights Reserved by MedPath